🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524376-36-00
Authorised Phase I

Bioequivalence study comparing two temazepam 20 mg tablet formulations after fasted administration; an open, randomized, single centre, single dose study with crossover design in healthy subjects

2025-524376-36-00 · tracked via the Priya Life Science EU tracker
Sponsor
Orion Corporation
Sponsor type
Pharmaceutical company
Therapeutic area
Nervous System Diseases
Decision date
05/05/2026
Enrollment target
24
Sites
Czechia

Condition studied

short-term treatment of insomnia

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524376-36-00 on CTIS ↗ ← All trials in the EU